Intuitive Surgical, Inc. (ISRG) Q3 2025 Earnings Call Transcript

Intuitive Surgical (ISRG) reported a robust Q3 2025, with revenue increasing 23% to $2.51 billion and pro forma EPS rising 30% to $2.40. This strong performance was driven by 20% total worldwide procedure growth, including 19% for da Vinci and 52% for Ion, alongside significant adoption of the da Vinci 5 system, which saw 240 placements and now has an installed base of 929 systems. The company raised its full-year 2025 guidance for da Vinci procedure growth to 17-17.5% and pro forma gross margin to 67-67.5%, citing strong utilization and efficiency gains from da Vinci 5, despite continued declines in U.S. bariatric procedures and a constrained Chinese market.

Analysis

Intuitive Surgical reported a robust Q3 2025, with revenue increasing 23% year-over-year to $2.51 billion and pro forma earnings per share rising 30% to $2.40, reflecting strong operational execution. This performance was underpinned by a 20% total worldwide procedure growth, including a 19% increase in da Vinci procedures and a significant 52% surge in Ion procedures, indicating broad-based adoption across its portfolio. The company also achieved a pro forma operating margin of 39%, demonstrating effective cost management despite some gross margin pressure.

The da Vinci 5 system emerged as a key catalyst, with 240 placements in Q3, contributing to an installed base of 929 systems and driving increased domestic demand for system upgrades. Its advanced capabilities, including force sensing and enhanced surgeon autonomy, are validating design intent and contributing to higher utilization rates, with da Vinci utilization growing 4% for multiport platforms. Furthermore, the company is strategically leveraging refurbished Xi systems to expand market access in cost-sensitive segments and alternative care sites, such as ASCs.

Intuitive Surgical raised its full-year 2025 guidance for da Vinci procedure growth to a range of 17% to 17.5% and pro forma gross margin to 67% to 67.5%, signaling continued confidence. While facing persistent high single-digit declines in U.S. bariatric procedures and a constrained, competitive market in China, the company's focus on innovation, digital tools, and international expansion, including initial da Vinci 5 placements in Japan and Europe, positions it for sustained growth. The planned direct market entry in Italy, Spain, and Portugal in H1 2026 is also expected to be accretive to pro forma EPS.

Key Decisions for Investors

• Investors should monitor the sustained procedure growth rates and increasing utilization of the da Vinci 5 system as key indicators of market penetration and competitive advantage, particularly its global rollout and adoption.
• Evaluate the impact of da Vinci 5's efficiency gains on long-term utilization trends and the strategic role of refurbished Xi systems in expanding market access, especially in ASCs and international markets.
• Assess the company's ability to mitigate headwinds from declining U.S. bariatric procedures and the challenging Chinese market, while considering the accretive impact of direct market entry in Europe and ongoing R&D in new disease states.